Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer.
Wilkins A, Stuttle C, Hassan S, Blanchard C, Cruickshank C, Griffin C, Probert J, Corbishley CM, Parker C, Dearnaley D, Hall E. Wilkins A, et al. Among authors: stuttle c. Clin Transl Radiat Oncol. 2018 Feb 16;10:1-6. doi: 10.1016/j.ctro.2018.02.002. eCollection 2018 Mar. Clin Transl Radiat Oncol. 2018. PMID: 29928699 Free PMC article.
Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.
Wilkins AC, Gusterson B, Szijgyarto Z, Haviland J, Griffin C, Stuttle C, Daley F, Corbishley CM, Dearnaley DP, Hall E, Somaiah N; CHHiP Trial Investigators. Wilkins AC, et al. Among authors: stuttle c. Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):309-315. doi: 10.1016/j.ijrobp.2018.01.072. Epub 2018 Feb 3. Int J Radiat Oncol Biol Phys. 2018. PMID: 29559283 Free PMC article. Clinical Trial.
Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
Wilkins A, Gusterson B, Tovey H, Griffin C, Stuttle C, Daley F, Corbishley CM, Dearnaley D, Hall E, Somaiah N. Wilkins A, et al. Among authors: stuttle c. EBioMedicine. 2023 Feb;88:104436. doi: 10.1016/j.ebiom.2023.104436. Epub 2023 Jan 26. EBioMedicine. 2023. PMID: 36708693 Free PMC article.
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer.
Fernandez-Mateos J, Cresswell GD, Trahearn N, Webb K, Sakr C, Lampis A, Stuttle C, Corbishley CM, Stavrinides V, Zapata L, Spiteri I, Heide T, Gallagher L, James C, Ramazzotti D, Gao A, Kote-Jarai Z, Acar A, Truelove L, Proszek P, Murray J, Reid A, Wilkins A, Hubank M, Eeles R, Dearnaley D, Sottoriva A. Fernandez-Mateos J, et al. Among authors: stuttle c. Nat Cancer. 2024 Sep;5(9):1334-1351. doi: 10.1038/s43018-024-00787-0. Epub 2024 Jul 12. Nat Cancer. 2024. PMID: 38997466 Free PMC article.
A four-group urine risk classifier for predicting outcomes in patients with prostate cancer.
Connell SP, Yazbek-Hanna M, McCarthy F, Hurst R, Webb M, Curley H, Walker H, Mills R, Ball RY, Sanda MG, Pellegrini KL, Patil D, Perry AS, Schalken J, Pandha H, Whitaker H, Dennis N, Stuttle C, Mills IG, Guldvik I; Movember GAP1 Urine Biomarker Consortium; Parker C, Brewer DS, Cooper CS, Clark J. Connell SP, et al. Among authors: stuttle c. BJU Int. 2019 Oct;124(4):609-620. doi: 10.1111/bju.14811. Epub 2019 Jun 25. BJU Int. 2019. PMID: 31106513 Free PMC article.